Lantheus' LNTH-2513 PET/CT Wins SNMMI Image of the Year for DVT Detection
Event summary
- Lantheus' LNTH-2513 (18F-GP1) PET/CT imaging agent won SNMMI’s Image of the Year at the 2026 Annual Meeting for detecting acute lower-extremity deep vein thrombosis (DVT).
- The investigational agent demonstrated 95% sensitivity and 92% specificity for proximal DVT in a 46-patient study, outperforming conventional venous ultrasonography (VUS).
- LNTH-2513 identified concomitant pulmonary embolism in 22 of 46 patients, including cases missed by VUS.
- No drug-related adverse events were reported, highlighting its safety profile.
The big picture
Lantheus' SNMMI award underscores the potential of thrombus-specific PET/CT imaging to improve DVT detection, addressing limitations of current standards like venous ultrasonography. The recognition could accelerate regulatory and commercial momentum for LNTH-2513, positioning Lantheus as a leader in advanced diagnostic radiopharmaceuticals. The broader trend toward precision imaging in vascular disease highlights the strategic value of this innovation.
What we're watching
- Regulatory Pathway
- Whether LNTH-2513 can secure FDA approval and expand into broader thromboembolic disease detection.
- Market Adoption
- The pace at which LNTH-2513 gains reimbursement and replaces conventional imaging in DVT diagnosis.
- Competitive Positioning
- How Lantheus leverages this milestone to differentiate itself in the radiopharmaceutical space.